| Literature DB >> 34126315 |
Syed Lal Badshah1, Shah Faisal2, Akhtar Muhammad2, Benjamin Gabriel Poulson3, Abdul Hamid Emwas3, Mariusz Jaremko4.
Abstract
Flavonoids are natural phytochemicals known for their antiviral activity. The flavonoids acts at different stages of viral infection, such as viral entrance, replication and translation of proteins. Viruses cause various diseases such as SARS, Hepatitis, AIDS, Flu, Herpes, etc. These, and many more viral diseases, are prevalent in the world, and some (i.e. SARS-CoV-2) are causing global chaos. Despite much struggle, effective treatments for these viral diseases are not available. The flavonoid class of phytochemicals has a vast number of medicinally active compounds, many of which are studied for their potential antiviral activity against different DNA and RNA viruses. Here, we reviewed many flavonoids that showed antiviral activities in different testing environments such as in vitro, in vivo (mice model) and in silico. Some flavonoids had stronger inhibitory activities, showed no toxicity & the cell proliferation at the tested doses are not affected. Some of the flavonoids used in the in vivo studies also protected the tested mice prophylactically from lethal doses of virus, and effectively prevented viral infection. The glycosides of some of the flavonoids increased the solubility of some flavonoids, and therefore showed increased antiviral activity as compared to the non-glycoside form of that flavonoid. These phytochemicals are active against different disease-causing viruses, and inhibited the viruses by targeting the viral infections at multiple stages. Some of the flavonoids showed more potent antiviral activity than the market available drugs used to treat viral infections.Entities:
Keywords: Flavonoids; Inhibitors; Natural products; Replication; Viruses
Year: 2021 PMID: 34126315 PMCID: PMC8192980 DOI: 10.1016/j.biopha.2021.111596
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529
Antiviral activities of flavonoids.
| S/N | Flavonoid | Structure | Virus | Experiment Model | Inhibitory Concentration IC50/EC50 | Cytotoxic Concentration CC50 | Inhibition Stage | Mode of inhibitory action | Ref |
|---|---|---|---|---|---|---|---|---|---|
| Taxifolin | Ebola Virus | Glide (binding) energy of - 47.57 kcal/mol with VP24 and − 37.433 kcal/mol for VP35 | – | VP24 & VP35 Viral surface Protein inhibition | Blocking the active site of VP24&35 which suppresses host interferon production. | ||||
| Sodium Rutin Sulfate | Human Immune Virus-1 | >3048.1 μM for Hela cells. | Viral Entry | Inhibition of Glycoproteins of HIV-1 Envelop. | |||||
| Strain 1: HIV-1×4 virus IIIB | IC50 = 2.3 ± 0.2 μM | >2589.5 μM for PBMC cells. | |||||||
| strain 2 HIV-1Ada-M | IC50 = 8.5 ± 3.8 μM | >1481.4 ± 355.6 for C8166 cells. | |||||||
| Strain 3: HIV-1 R5 | IC50 = 13.1 ± 5.5 μM | ||||||||
| HSV-1 | IC50 = 88.3 ± 0.1 μM | > 3.0 mM | Not reported | Not reported | |||||
| Ro-090179 | Polio Virus PV-1 | 1.5 μM Prevented appearance of viral proteins (IC50 not reported) | Not reported | Viral RNA Replication | strong blockade of poliovirus plus-stranded viral RNA synthesis | ||||
| Rhoifolin | SARS-CoV-1 | IC50 = 27.24 μM | Not reported | Inhibition of SARS-CoV 3CLprotease enzyme. | Blocking of active sites of Protease enzyme | ||||
| Quercetin-3 ß-O- | Ebola virus Strain:1 EBOV Makona | EC50 = 5.3 μM | 100 μM showed no toxicity to Vero E6 cells | Entry and Replication | Inhibited Envelop proteins of Ebola virus and its Replication. | ||||
| Strain:2 MA-EBOV | 50 mg/kg | Less than 100 mg/kg Mice model | |||||||
| (-) Gallocatechin gallate (GCG) | HSV-1 | 3.5 log reduction | No cytotoxicity at 100 μM to both Vero and CV-1 cells | Entry | Inhibition of gB and gD viral Envelop proteins of HSV-1,2 | ||||
| HSV-2 | 4.0 log reduction | ||||||||
| Quercetin 7-rhamnoside | (PEDV) Porcine epidemic diarrhea virus | IC50 = 0.014 μg /ml | CC50 = 100 μg /ml against Vero cells | Replication | Early stage of Viral Replication | ||||
| Quercetin 3-rhamnoside | Influenza virus strain-A/WS/33 | Not reported | Not reported | Replication | Early stage of Viral Replication | ||||
| Quercetagetin | (CHIKV)Chikungunya virus | IC50 = 13.53 µg/ml | CC50 = 52.42 μg/ml for BHK-21 cells | Replication | Multi-stage inhibition. Extracellular inhibition of CHIKV, Blocking its attachment to host cells, inhibition of CHIKV replicon system. | ||||
| IC50 = 9.934 µg/ml | Extracellular stage | ||||||||
| IC50 = 8.050 µg/ml | Entry | ||||||||
| Pinocembrin | Zika virus (ZIKV) | IC50 = 17.4 μM | CC50 = 251 μM for JEG-3 cells | Replication | Inhibition of positive+ and negative-sense ZIKV RNA synthesis | ||||
| Pectolinarin | SARS-CoV-1 | IC50 = 27.24 μM | Not reported | Poly-protein processing. | Inhibition of SARS-CoV 3CLprotease which is main protease enzyme in SARS-CoV-1 | ||||
| Naringenin | Hepatitis C virus (HCV) | 80% inhibition at a concentration of 200 μM. IC50 is not reported. | More than 200 μM against Huh7.5.1 cells | Secretion from infected cells | Inhibition of HCV secretion from infected host cells by host factor modulation. | ||||
| Myrciatrin V | Ebola virus | ∆G-binding values of −9,1728 kcal/mol | – | Entry and attachment | In-silico simulation showed strong interaction and attachment of Myrciatrin V with the envelop glyco-proteins (GP) of Ebola virus. | ||||
| Luteolin | Coxsackieviruses (CA-16) | EC50 = 10.52 μM | CC50 = 148.02 μM Against RDS cells | Replication | Inhibition of post entry stage by targeting the Viral RNA replication. | ||||
| Leachianone G | HSV-1 Herpes simplex virus-1 | IC50 = 1.6 μg/ml | CC50 = 15.5 μ g/ml against Vero cells | Not reported | Not reported | ||||
| Ladanein (BJ486K) | HCV strains: 1a&1b, 2b as well 3a, 4a, 5a, & 6a | IC50 = 2.5μmol/L | CC50 = 98.04 μmol/L Against Huh7-Lunet/CD81 cells | Entry | Inhibition of post attachment entry into the host cells | ||||
| Kaempferol | Enterovirus EV-A71 | At a concentration of 35 μM for 24 h, 80% virus activity decreased | Greater than 50 μM against RD cells | Replication | Interference with the Replication process of the Virus | ||||
| Its IC50 is not reported. | |||||||||
| SARS-CoV-1 | At 20 μM Kaempferol decreased the 3a channel activity by factor of 3–5 times. | Not reported | Secretion of virus from host cells | Inhibition of the 3a-channel protein, which is used for virus release from host cells | |||||
| Juglanin | SARS‐CoV-1 | IC50 = 2.3 μM | Not reported | Secretion of virus from host cells | Blocking of the 3a-channel protein, which is used for virus release from host cells | ||||
| Herbacetin | SARS‐CoV-1 Coronavirus | IC50 = 33.17 μM | Not reported | Poly-protein processing | Inhibition of SARS-CoV-1 3CL-protease enzyme required for viral poly-protein processing | ||||
| Gossypetin | Ebola Virus | Glide (binding) energy of −34.633 Kcal/mol with VP24 Glide (binding) energy of −31.628 Kcal/mol Kcal/mol with VP35 | – | VP24 & VP35 Viral Protein inhibition | Blocking the active site of VP24&35 which suppresses host interferon production. | ||||
| Genistein | HIV-1 | 80 μM caused 50% inhibition. | Not reported | Virus release from infected host cells | Blocking of Vpu-Ion-channel (viral-protein-U), which is necessary for virus release from infected host cells. | ||||
| HCMV Cytomegalovirus | IC50 = 38 μM | CC50 = 100 μM for HEL 299 | Replication | DNA synthesis by interfering with DNA-polymerase | |||||
| HSV-1 | EC50 = 1.35 μg/ml | CC50 = 250 μM (Vero cells) | Not reported | Reduction in CPE | |||||
| Galangin | HSV-1 | EC50 = 0.64 μg/ml | CC50 = 1000 μM (Vero cells0 | Not reported | Reduction in CPE | ||||
| Fisetin | CHIKV Chikungunya virus | IC50 = 8.44 µg/ml | CC50 were 194.45 μg/ml | Intracellular stage | Targeted the Replication process of Virus | ||||
| Epigallocatechin Gallate (EGCG) | HBV | IC50 = 39.4 μ mol/L | No cytotoxicity at 100 μmol/L to HepG2.117 cells | Envelop proteins & Replication | Reduction in Precore-mRNA & HBeAg. | ||||
| ZIKV Zika virus | EC50 = 21.4 μM | Entry | Blocking of Envelop proteins | ||||||
| HSV-1 | IC50 = 12–25 μM For different HSV-1 Strains | > 100 μM (Vero & CV-1 cells) | Entry | Inhibition of gB and gD viral Envelop proteins of HSV-1,2 | |||||
| HSV-2 | IC50 = 6–12.5 μM For different HSV-2 Strains | ||||||||
| Epicatechin gallate | HSV-1 | EC50 = 0.72 μg/ml | CC50 = 500 μM (Vero cells) | Reduction in CPE | |||||
| Dihydroquercetin | Coxsackievirus - B4 strain | 75–150 mg/kg/day for 5-days (p.i) | Not reported | Replication | Suppression of Viral Replication process. | ||||
| Influenza Virus H1N1 | IC50 = 2.8 μg/ml | Not reported | Viral attachment | Blocking of Viral surface protein attachment to host cells | |||||
| cyanidin-3-(p-coumaroyl)-rutinoside-5-glucoside | Sudan Ebolavirus SEBOV | ∆G-binding value −9,6941 kcal/mol | – | Entry and attachment | In-silico simulation showed strong interaction and attachment of this Flavonoid with the envelop glyco-proteins (GP) of Ebola virus. | ||||
| Baicalin | HIV-1 | 4 μM causes 50% inhibition. (IC50 not reported) | Not reported | Entry | Inhibition of HIV-1 Env-Protein | ||||
| DENV-2 | IC50 = 14.9 μg/ml | CC50 = 290.9 μg/ml (Vero cells) | Intracellular | Inhibition of Nsps of Ebola Virus | |||||
| IC50 = 13.50 μg/ml | replication | Not reported | |||||||
| Enterovirus EV-A71 | IC50 = 4.96 μg/ml | CC50 = 823.53 μg/ml (RD Cells) | Replication | Inhibition of Polymerase | |||||
| Amentoflavone | Coxsackie virus B3 | IC50 = 19 ± 1.6–41 ± 1.2 μg/ml | CC50 = 53 ± 0.9 μg/ml (HEp-2 cells) | – | Direct virucidal effect. | ||||
| SARS-CoV-1 | IC50 = 8.3 μM | Not reported | Poly-Protein processing | Inhibition of SARS-CoV 3CLprotease enzyme. | |||||
| Apigenin | HCV | At 5 μM significant inhibition was noted(IC50 not reported) | Not reported | Replication | Inhibition of gene expression of miRNA122. | ||||
| Entero virus EV-71 | EC50 of 10.3 μM | CC50 = 79.0 μM RD Cells | Host factor modulation | Viral RNA association with hnRNP A1 and A2 proteins | |||||
| Entero virus EV-71 | 50 mg/Kg Mice model (88.89% survival rate) | Not reported | Replication & Protein synthesis | Viral genomic RNA inhibition | |||||
| Baicalein | HCMV | IC50 = 0.4 ± 0.04 μM | CC50 = 100 μM | Replication | Inhibition of immediate early proteins | ||||
| CHIKV | IC50 = 3.243 µg/ml | CC50 356.65 μg/ml (BHK-21 cells) | Replication | CHIKV replicon | |||||
| IC50 = 9.934 µg/ml | Extracellular | Adsorption | |||||||
| IC50 = 1.891 µg/ml | Replication of CHIKV | ||||||||
| JEV | IC50 = 7.27 ± 1.08 μg/ml | CC50 = 115.2 ± 0.2 μg/ml | Replication | Inhibition of Viral RNA synthesis | |||||
| IC50 = 5.8 ± 1.09 μg/ml | Entry | Blocking of internalization | |||||||
| 7-O-(6-feruoylglucosyl)isoorientin | Sudan Ebola virus SEBOV | ∆G-binding values of −9.0058 kcal/mol | – | Entry and attachment | In-silico simulation showed strong interaction and attachment of this Flavonoid with the envelop glyco-proteins (GP) of Ebola virus | ||||
| 6-chloro-4′-oxazolinyl flavanone | Polio-virus type-2 | IC50 = 2.791 μM | > 12.5 μM (Hela Cells) | Plaque reduction | Inhibition of viral replication | ||||
| Human Rhino Virus (HRV-1B) | IC50 = 5.161 μM | > 12.5 μM (Hela Cells) | Plaque reduction | Inhibition of viral replication | |||||
| 6-chloro-3-Methoxyflavone-4′-carboxylic acid | Human Rhino Virus (HRV-1B) | IC50 = 3.82 μM | > 25 μM (Hela Cells) | Plaque reduction | Inhibition of viral replication | ||||
| 6-Chloro-3-methoxy-4′-oxazolinylflavone | Human Rhino Virus (HRV-1B) | IC50 = 4.47 μM | > 25 μM (Hela Cells) | Plaque reduction | Inhibition of viral replication | ||||
| 6-chloro-3-hydroxyflavone-4′-carboxylic acid | Polio virus PV-2 | IC50 = 1.91 μM | > 12.5 μM (Hela Cells) | Plaque reduction | Inhibition of viral replication | ||||
| 5,7,3′,4′-tetra-O-methylquercetin | Influenza virus H1N1 | IC50 = 0.13 μg/ml | Not reported | Viral attachment | Blocking of Viral surface Glyco-proteins and its attachment to host cells | ||||
| 3-methyl Quercetin | Polio Virus PV-1 Mahoney strain | 1.5 μM Prevented appearance of viral proteins (IC50 not reported) | Not reported | Viral RNA Replication | strong blockade of poliovirus plus-stranded RNA synthesis | ||||
| (-)Epigallocatechin (EGC) | Influenza A&B | 1–3 log reduction (IC50 not reported) | CC50 = 400 μg /ml on MDCK cells | Intracellular | prevention of acid-catalyzed fusion reaction of Virus | ||||
| HSV-1 | EC50 = 0.725 μg/ml | No cytotoxicity At 100 μM to Vero cells | Not reported | Reduction in CPE | |||||
| (-)Epicatechin | HSV-1 | EC50 = 0.725 μg/ml | No cytotoxicity At 100 μM to Vero cells | Not reported | Reduction in CPE | ||||
| Quercetin | Influennza-A | ||||||||
| 1)A/Puerto Rico/8/34 strain | IC50 = 7.756 μg/ml | Higher than 250 μg/ml For MDCK Cells | Entry | Blocking of Hemagglutinin (HA) Glycoprotein (GP) | |||||
| 2) A/FM-1/47/1 strain | IC50 = 6.225 μg/ml | ||||||||
| 3) A/Aichi/2/68 (H3N2) | IC50 = 2.738 μg/ml | ||||||||
| DENV-2 | IC50 = 35.7 μg /ml | 252.6 ± 0.17 μg/ml for Vero cells | Replication | Reduction of Viral RNA levels | |||||
| HCV | 10 μg/ml | No cytotoxicity at a concentration of 10 μg/ml | Replication and NS3 protease | Blocking of both the RNA synthesis and NS3 protease enzyme | |||||
| Cardio Virus different strains | 80–240 mg/kg | No toxicity at 240 mg/kg in mice model | Immune-mediated infection control | Macrophage activation | |||||
| Rhino Virus | 10 μg /ml | Not reported | Transcription | Inhibition of endocytosis and PI-3 Kinase | |||||
| HSV-1&2 | EC50 = 1.69 μg/ml | No cytotoxicity on Vero cells up to of 100 μM | Not reported | Reduction in CPE caused by HSV-1&2 | |||||
| Ebola Virus EBOV | IC50 = 7.4 μM | CC50 was greater than 100 μM for HEK293T cells | Inhibition of VP24 protein | Restoration of immune system by InhibitingVP24 viral protein | |||||
| Zika virus | IC50 = 2.30 μM | CC50 = >500 μM Vero cells | Replication | Targeting ZIKV RNA production | |||||
| Myricetin | Zika virus | IC50 = 0.58 μM | CC50 = >500 μM Vero cells | Replication | Targeting ZIKV RNA production | ||||
| Isoquercitrin | Zika virus | IC50 = 9.7 ± 1.2 μM | CC50 = 582.2 ± 41.4 μM for SH-SY5Y cells | Entry | Blocked virus internalization into host cells | ||||
| Silymarin | HCV | 5–20 mg/kg infusions | Not reported | Replication | By inhibition of HCV RNA replicon | ||||
| Influenza-A,B | At 100 μg/ml concentration 98% inhibition was noted | No cytotoxicity at 100 μg/ml to MDCK cells | Replication | By targeting the Viral RNA synthesis process | |||||
| Sorbifolin | HCV | 45.0% efficient at inhibiting viral entry | No cytotoxicity towards the tested cells. | Entry | Virucidal effect | ||||
| Pedalitin | HCV | 78.7% efficient at inhibiting viral entry | No cytotoxicity towards the tested cells | Entry | inhibit virus entry by interfering with virus and host cell. |
(IC) The half-maximal inhibitory concentration is a measure of a substance's ability to inhibit biological activity.
(EC) Half-maximal effective concentration is the concentration required to obtain a 50% effect.
(CC) is the compound's concentration required for reducing cell viability by 50%.
Active Flavonoids against Coronavirus SARS-CoV-2.
| S.No | Virus | Flavonoid | Experiment model | IC50/Binding Energies | Inhibition target |
|---|---|---|---|---|---|
| 1 | Coronavirus. SARS-CoV-2 | Epigallocatechin Gallate (EGCG) | IC50 = 7.58 μg/ml | Main protease-MPro | |
| 2 | Theaflavin | IC50 = 8.44 μg/ml | Main protease-MPro | ||
| 3 | Myricitrin | Binding energy = −8.9 kcal/mol | Main protease-MPro | ||
| 4 | Taiwanhomoflavone A | Binding energy = −9.6 kcal/mol | RNA-dependent RNA-Polymerase (RdRp) and Human Angiotensin Converting Enzyme-2 (hACE-2) | ||
| 5 | Rutin | Binding energy = −8.2072 kcal/mol | Main protease-MPro | ||
| 6 | Fisetin | binding affinity score= −8.5 kcal/mol | spike protein | ||
| 7 | Biochanin A | Docking energy score= −78.41 | Protease domain-ACE-2 & RBD-Spike protein | ||
| 8 | Silymarin | Docking energy score= −121.28 kcal/mol | Protease domain-ACE-2 & RBD-Spike protein | ||
| 9 | Quercetin | binding affinity score= −8.5 kcal/mol | spike protein | ||
| binding affinity score= −9.2 kcal/mol | Main protease-MPro | ||||
| 10 | Narcissin | binding affinity score= −8.2530 and | Main protease-MPro | ||
| 11 | kaempferol-3-O-rutinoside | binding affinity score= −8.1203 kcal/mol | Main protease-MPro | ||
| 12 | Naringin | binding energy = −9.8 kcal/mol | Spike protein |
(IC50) The half-maximal inhibitory concentration is a measure of a substance's ability to inhibit biological activity. Binding affinity, energy scores are the energy values when a ligand bind to a protein in Molecular Docking studies, Or The binding free energy is defined as the sum of the ligand's inter-molecular interactions with the protein and the ligand's internal steric energy.
Fig. 1General structure of a flavonoid.
Fig. 2Synthesis of Flavonoids Using Baker–Venkataraman rearrangement.
Fig. 3(a) Synthesis of fluorinated ketone intermediates. (b) Synthesis of 6-fluoroflavone. (c) Synthesis of 6-Fluoroflavanone through acetic acid.
Fig. 4(a) Initial Steps of synthesis of starting material for flavonoids. (b) Synthesis of chalcone for making flavonoids derivatives.
Fig. 5Synthesis of flavanone and flavonoids.
Fig. 6Synthesis of myricetin derivatives with antiviral activities against tobacco mosaic virus.
Comparison of the inhibitory concentration of flavonoids & standard antiviral compounds.
| S/N | Flavonoid | Inhibitory Concentration | Standard Drug | Inhibitory Concentration | Virus | Ref. |
|---|---|---|---|---|---|---|
| 1 | Silymarin | 10 mg/kg/day | Ribavarin+IFN | 10–20 mg/kg/day | HCV | |
| 2 | Genistein | 0.4 μg/ml | Acyclovir | 1.6 μg/ml | PI-3 | |
| 3 | Quercetin | 0.2 μg/ml | Acyclovir | 1.6 μg/ml | HSV-1 | |
| 4 | 5, 7, 30, 40-tetra-O-methylquercetin | 0.36 μM | Oseltamivir | 0.32 μM | H1N1 | |
| 5 | Apigenin | 1.6 μg/ml | Acyclovir | 1.6 μg/ml | HSV-1 | |
| 6 | Fisetin | 8.444 µg/ml | Ribavirin | 11.07 µg/ml | CHIKV | |
| 7 | Silymarin | 100 μg/ml 98% Inhibition | Oseltamivir | 100 μg/ml 52%- inhibition | H1N1 | |
| 8 | Leachianone-G | 1.6 μg/ml | Acyclovir | 1.6 μg/ml | HSV-1 | |
| 9 | Galangin | 0.64 μg/ml | Acyclovir | 1.6 μg/ml | HSV-1 | |
| 10 | Baicalein | 1.891 µg/ml | Ribavirin | 11.07 µg/ml | CHIKV | |
| 11 | Q7R | 0.014 μg/ml | Ribavirin | 4.1 μg/ml | PEDV | |
| 12 | Silibinin | 1.6 μg/ml | Oseltamivir | 1.6 μg/ml | PI-3 | |
| 13 | Narinen | 0.2 μg/ml | Oseltamivir | 1.6 μg/ml | PI-3 | |
| 14 | Quercetin | 1.69 μg/ml | Acyclovir | 1.6 μg/ml | HSV-1 | |
| 15 | Genistein | 1.35 μg/ml | Acyclovir | 1.6 μg/ml | HSV-1 | |
| 16 | DHQ | 75–150 mg/kg/day | Ribavirin | 75–150 mg/kg/day | CV-B4 |